| Literature DB >> 35743456 |
Hye-Min Sohn1, Hyoeun Ahn1, Won-Seok Seo1, In-Kyung Yi1, Jun Yeong Park2.
Abstract
Perioperative cerebral hypoperfusion/ischemia is considered to play a pivotal role in the development of secondary traumatic brain injury (TBI). This prospective randomized, double-blind, controlled study investigated whether magnesium sulfate (MgSO4) infusion was associated with neuroprotection in maintaining regional cerebral oxygen saturation (rSO2) values in patients with mild TBI undergoing general anesthesia. Immediately after intubation, we randomly assigned patients with TBI to receive either intravenous MgSO4 (30 mg/kg for 10 min, followed by a continuous infusion of 15 mg/kg/h) or a placebo (saline) during surgery. We also implemented an intervention protocol for a sudden desaturation exceeding 20% of the initial baseline rSO2. The intraoperative rSO2 values were similar with respect to the median (left. 67% vs. 66%, respectively; p = 0.654), lowest, and highest rSO2 in both groups. The incidence (left 31.2% vs. 24.3%; p = 0.521) and duration (left 2.6% vs. 3.5%; p = 0.638) of cerebral desaturations (the relative decline in rSO2 < 80% of the baseline value) were also similar for both groups. Although the patients suffered serious traumatic injuries, all critical desaturation events were restored (100%) following stringent adherence to the intervention protocol. Intraoperative remifentanil consumption, postoperative pain intensity, and fentanyl consumption at 6 h were lower in the MgSO4 group (p = 0.024, 0.017, and 0.041, respectively) compared to the control group, whereas the satisfaction score was higher in the MgSO4 group (p = 0.007). The rSO2 did not respond to intraoperative MgSO4 in mild TBI. Nevertheless, MgSO4 helped the postoperative pain intensity, reduce the amount of intraoperative and postoperative analgesics administered, and heighten the satisfaction score.Entities:
Keywords: analgesia; cerebral oxygen saturation; magnesium; multiple trauma; near-infrared; neuroprotection; opioid consumption; spectroscopy; traumatic brain injury
Year: 2022 PMID: 35743456 PMCID: PMC9225065 DOI: 10.3390/jcm11123388
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1CONSORT diagram.
Baseline characteristics of patients and perioperative data assigned to magnesium or the control group.
| Magnesium Group ( | Control Group ( | ||
|---|---|---|---|
| Sex (Male/Female) | 25/7 | 32/5 | 0.361 |
| Age (year) | 49.5 ± 15.2 | 50.1 ± 14.9 | 0.879 |
| Height (cm) | 168.5 ± 7.2 | 167.9 ± 8.1 | 0.749 |
| Weight (kg) | 71.9 ± 11.6 | 69.9 ± 11.4 | 0.479 |
| ASA (I/II/III) | 3/18/11 | 3/28/6 | 0.211 |
| Mechanism of Injury, | 0.642 | ||
| Fall | 11 (34.4%) | 11 (29.7%) | |
| Transportation accident | 20 (62.5%) | 26 (70.3%) | |
| Explosion | 1 (3.1%) | 0 (0%) | |
| Days after injury (days) (range) | 4.5 ± 3.7 | 5.1 ± 4.7 | 0.569 |
| Surgery, Orthopedic | 0.315 | ||
| Upper extremity | 11 (34.4%) | 9 (24.3%) | |
| Lower extremity | 12 (37.5%) | 15 (40.5%) | |
| Hip | 4 (12.5%) | 4 (10.8%) | |
| Other parts | 4 (12.5%) | 6 (16.2%) | |
| Combined op | 1 (3.1%) | 3 (8.1%) | |
| Magnesium at admission (normal range: 1.6–2.6) (mg/dL) | 1.96 ± 0.41 | 2.03 ± 0.20 | 0.361 |
| Duration of surgery (min) | 81.1 ± 43.0 | 99.6 ± 63.3 | 0.167 |
| Duration of anesthesia (min) | 126.4 ± 49.0 | 143.1 ± 66.7 | 0.247 |
| Aldrete score * | 10 ( | 10 ( | |
| PACU stay time (min) * | 34.6 ± 7.7 ( | 37.8 ± 9.9 ( | 0.239 |
ASA, American Society of Anesthesiologists; PACU, post-anesthesia care unit. Values are number (proportion) or mean ± SD. * only those who have been transferred to PACU after surgery.
Traumatic brain injury aspects preoperatively.
| Magnesium Group ( | Control Group ( | ||
|---|---|---|---|
| TBI, Symptom, | |||
| Loss of consciousness at the time of injury | 24 (75.0%) | 33 (89.2%) | 0.121 |
| Headache | 6 (18.8%) | 8 (21.6%) | 0.767 |
| Dizziness | 3 (9.4%) | 6 (16.2%) | 0.489 |
| Nausea/vomiting | 5 (15.6%) | 5 (13.5%) | 0.804 |
| Memory impairment | 5 (15.6%) | 6 (16.2%) | 0.947 |
| Sleeping tendency | 10 (31.3%) | 13 (35.1%) | 0.733 |
| TBI, Severity, | |||
| Mild (GCS 15/14) | 31/1 | 34/3 | 0.618 |
| Moderate | 0 | 0 | |
| Severe | 0 | 0 | |
| Brain CT, | |||
| Subarachnoid hemorrhage | 8 (25.0%) | 5 (13.5%) | 0.224 |
| Subdural hemorrhage | 6 (18.8%) | 4 (10.8%) | 0.350 |
| Epidural hemorrhage | 4 (12.5%) | 2 (5.4%) | 0.349 |
| Intracerebral hemorrhage | 0 (0%) | 1 (2.7%) | 0.279 |
| Cerebral Contusion | 2 (6.3%) | 4 (10.8%) | 0.503 |
| Skull fracture | 7 (21.9%) | 3 (8.1%) | 0.105 |
| Scalp/soft tissue swelling | 8 (25.0%) | 14 (37.8%) | 0.254 |
| Midline shift > 5 mm, | 0 | 0 | |
| The others | 4 (12.5%) | 3 (8.1%) | 0.547 |
| No intracranial hemorrhage or bony skull fracture | 16 (50.5%) | 17 (51.5%) | 0.737 |
| TBI site (Left/Right/Both/non-specific/none) | (3/9/4/0/16) | (4/4/4/8/17) | |
| Preoperative antiepileptic prescription | 10 (31.3%) | 6 (16.2%) | 0.140 |
| GCS at the time of entering trauma-bay | 14.16 ± 2.02 | 14.62 ± 0.83 | 0.210 |
| 15/14/13–11/less than 11, | 24/6/1/1 | 21/11/4/1 | |
| GCS at the time of leaving trauma-bay | 14.62 ± 0.73 | 14.74 ± 0.56 | 0.451 |
| 15/14/13–11/less than 11, | 26/3/0/3 | 23/8/4/2 | |
| Invasive ICP monitoring, | 0 | 0 | |
| Evacuation of brain mass lesion, | 0 | 0 | |
| ISS score | |||
| Median (range, IQR) | 22 (5–43, 17–23) | 19 (9–43, 17–22) | |
| Mean ± SD | 21.2 ± 6.7 | 22.0 ± 9.3 | 0.691 |
TBI, traumatic brain injury; GCS, Glasgow Coma Scale; CT, computed tomography; ICP, intracranial pressure; ISS, injury severity score; IQR, interquartile range. Values are number (proportion) or mean ± SD. * Allow duplicate counts because of concurrent brain injuries identified by CT scan.
Figure 2Representative values of regional cerebral oxygen saturation (rSO2) in the operating room. (a) Time trend of rSO2. T0: baseline at admission to operating room (OR), T1: Mg bolus administration, T2: Mg continuous infusion, T3–T6: 10, 20, 30, 40 min after Mg infusion, T7: end of surgery, T8: leaving the OR. ● Left ▲ Right ● Magnesium ○ control. (b) Incidence of percentage decreases in rSO2 (%), below or equal to minus 20% and below or equal to 10% to less than 20% relative to each baseline value. (c) Duration of percentage decreases in rSO2 (%). The inner circle is the Magnesium group. The outer circle is the Control group. * p < 0.05 from baseline value in Magnesium (Mg) group, † p < 0.05 from baseline value in control group.
Postoperative analgesic consumption and pain scores during the first 48 h after surgery.
| Magnesium Group ( | Control Group ( | ||
|---|---|---|---|
| PCA fentanyl consumption | 0.322 | ||
| postoperative 6 h (mcg) | 201.9 ± 134.1 * | 302.8 ± 140.4 | 0.026 |
| postoperative 24 h (mcg) | 574.7 ± 380.7 | 598.6 ± 264.9 | 0.814 |
| postoperative 48 h (mcg) | 762.8 ± 464.4 | 853.8 ± 357.4 | 0.482 |
| Fentanyl bolus iv until 6 h postoperatively (mcg) | 0.495 | ||
| Nefopam consumption | 0.232 | ||
| postoperative 6 h (mg) | 21.6 ± 2.3 | 21.9 ± 2.5 | 0.700 |
| postoperative 24 h (mg) | 70.6 ± 8.5 | 71.9 ± 5.4 | 0.519 |
| postoperative 48 h (mg) | 86.2 ± 23.6 | 93.4 ± 8.1 | 0.137 |
| NSAIDs use, number (%) | |||
| postoperative 6 h | 5 (15.6%) * | 14 (37.8%) | 0.039 |
| postoperative 24 h | 6 (18.8%) | 8 (21.6%) | 0.767 |
| postoperative 48 h | 8 (25.0%) | 6 (16.2%) | 0.366 |
| Tramadol consumption | 0.330 | ||
| postoperative 6 h (mg) | 56.3 ± 50.4 | 49.3 ± 47.3 | 0.558 |
| postoperative 24 h (mg) | 120.3 ± 71.9 | 104.1 ± 76.7 | 0.370 |
| postoperative 48 h (mg) | 116.4 ± 65.6 | 127.0 ± 74.9 | 0.536 |
| Pain scores (NRS) | |||
| postoperative 6 h | 6.8 ± 2.8 * | 8.2 ± 2.0 | 0.017 |
| postoperative 24 h | 5.1 ± 2.5 | 5.4 ± 2.3 | 0.660 |
| postoperative 48 h | 3.3 ± 2.2 | 3.2 ± 2.6 | 0.839 |
| Satisfaction scores (NRS) | |||
| postoperative 6 h | 66.1 ± 28.9 * | 47.1 ± 27.6 | 0.007 |
| postoperative 24 h | 71.8 ± 21.1 | 65.7 ± 20.6 | 0.226 |
| postoperative 48 h | 78.3 ± 21.3 | 73.4 ± 24.6 | 0.389 |
PCA, patient-controlled analgesia; NSAIDs, nonsteroidal anti-inflammatory drugs; NRS, numeric rating scale. Values are mean ± SD. * p < 0.05 = between groups.